Related Experiment Video

Updated: Apr 24, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

944

Inhibiting CCN1 blocks AML cell growth by disrupting the MEK/ERK pathway

Chang-Chun Niu1, Chen Zhao2, Zhong Yang3

  • 1Department of Clinical Hematology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China ; Department of Clinical Laboratory, The Third People's Hospital of Chongqing, Chongqing 400014, China.

Cancer Cell International
|September 5, 2014
PubMed
Abstract

Insights

Cellular communication network factor 1 (CCN1) promotes acute myeloid leukemia (AML) growth by activating the MEK/ERK pathway, increasing c-Myc and Bcl-xL, and decreasing Bax. Inhibiting CCN1 suppressed leukemia cell proliferation and enhanced apoptosis.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • The role of CCN1 in various cancers is established, but its specific function in leukemia remains largely uncharacterized.
  • Understanding CCN1's involvement is crucial for developing targeted leukemia therapies.

Purpose of the Study:

  • To investigate the expression and function of CCN1 in acute myeloid leukemia (AML).
  • To determine the molecular mechanisms by which CCN1 influences AML cell growth and survival.

Main Methods:

  • Analyzed CCN1 protein expression in AML cell lines and patient bone marrow samples.
  • Utilized antibody- and siRNA-mediated inhibition of CCN1 to assess its impact on AML cell proliferation, apoptosis, and key signaling pathways (MEK/ERK, β-catenin).

Main Results:

  • Elevated CCN1 expression was observed in AML cell lines and patient samples compared to controls.
  • CCN1 inhibition suppressed proliferation, induced apoptosis, and modulated the expression of apoptosis-related genes (Bcl-xL, c-Myc, Bax).
  • CCN1 inhibition reduced MEK/ERK phosphorylation, suggesting a role in this signaling pathway.

Conclusions:

  • CCN1 acts as a tumor promoter in AML.
  • CCN1 promotes AML progression via the MEK/ERK pathway, influencing the expression of c-Myc, Bcl-xL, and Bax.
  • Targeting CCN1 presents a potential therapeutic strategy for AML.
Keywords:
AMLCCN1ERK

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

10.8K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

4.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K